Clinical Trials on Knowledge Translation

Total 599 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia

Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Minimal Residual Disease | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
Novartis Pharmaceuticals

Completed

An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Philadelphia Positive Chronic Myeloid Leukemia

United States, Germany, United Kingdom, France, Italy
Novartis Pharmaceuticals

Completed

A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL

Chronic Myelogenous Leukemia | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

Japan
Università Politecnica delle Marche

Not yet recruiting

Endobronchial Ultrasound Needle Aspiration With and Without Suction

Lymphoma | Lung Neoplasms | Tuberculosis | EGF-R Positive Non-Small Cell Lung Cancer | Sarcoidosis | Mediastinal Lymphadenopathy | Hilar Lymphadenopathy | ROS1 Gene Mutation | PDL1 Gene Mutation | ALK Translocation

Italy
The First Affiliated Hospital of Soochow University

Completed

Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Philadelphia Chromosome | Mixed Phenotype Acute Leukemia

China
Novartis Pharmaceuticals

Completed

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Germany, Australia, Netherlands, Spain, Korea, Republic of, France, Japan, Italy, Singapore, United States
OHSU Knight Cancer Institute
AbbVie; Oregon Health and Science University

Recruiting

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

B Acute Lymphoblastic Leukemia | Recurrent B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Mixed Phenotype Acute Leukemia

United States
Bradley A. McGregor, MD
Bristol-Myers Squibb; Exelixis

Recruiting

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

Renal Cell Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma | Collecting Duct Renal Cell Carcinoma | Translocation Renal Cell Carcinoma | Unresectable Advanced Renal Cell Carcinoma | Metastatic Ncc Renal Cell Carcinoma

United States
Montefiore Medical Center

Completed

Effect of Supine or Prone Position After Caesarean Birth

Transient Tachypnea of the Newborn | Respiratory Distress | Delayed Transition of the Newborn | Persistent Pulmonary Hypertension

United States
Crystal Mackall, MD

Recruiting

Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Positive | Refractory Acute Lymphoblastic Leukemia | Minimal Residual Disease | CD19 Positive

United States
Merck Sharp & Dohme LLC

Terminated

Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)

Blast Phase Philadelphia Chromosomes Positive (Ph+) Chronic Myelogenous Leukemia (CML) | Philadelphia Chromosome Positive (Ph+) Acute Lymphocytic Leukemia (ALL)
Northwestern University
National Cancer Institute (NCI)

Terminated

Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Refractory Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 | Refractory Childhood Acute Lymphoblastic Leukemia

United States
Novartis Pharmaceuticals

Terminated

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

Chronic Myeloid Leukemia (CML) | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) | Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)

Russian Federation
Bristol-Myers Squibb

Completed

Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Chronic Myeloid Leukemia | Leukemia, Lymphoblastic, Acute, Philadelphia-positive

Netherlands, United States, Italy, Argentina, Austria, Brazil, Canada, Germany, Peru, United Kingdom, France, Korea, Republic of, Sweden, Finland, Australia, Israel, Belgium, Denmark, Norway, Switzerland
National Cancer Institute (NCI)

Active, not recruiting

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia | Refractory Adult Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | T Acute Lymphoblastic Leukemia

United States
University of Helsinki
Royal Children's Hospital; Murdoch Childrens Research Institute; University of... and other collaborators

Active, not recruiting

Healthcare Transition of Adolescents With Chronic Health Conditions

Liver Diseases | Kidney Diseases | Diabetes | Rheumatic Diseases | Inflammatory Bowel Diseases | Neurologic Disorder | Congenital Heart Disease | Transition

Australia, Finland
Marlise Luskin, MD
Novartis

Recruiting

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

B-cell Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL

United States
Extremity Medical

Recruiting

The KinematX Midcarpal Total Wrist Arthroplasty Registry

Osteoarthritis | Inflammatory Arthritis | Carpal Tunnel Syndrome (CTS) | Post Traumatic Arthritis | Scapholunate Advanced Collapse (SLAC) | Scapholunate Crystalline Advanced Collapse (SCAC) | Scaphoid, Trapezium, and Trapezoid Advanced Collapse (STTAC) | Kienbock's Disease of Adults | Radial Malunion | Ulnar Translocation and other conditions

United States
Children's Oncology Group
Pfizer; Erasmus Medical Center; Dutch Childhood Oncology Group; Innovative Therapies...

Active, not recruiting

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Blastic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive CML

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia

Accelerated Phase Chronic Myelogenous Leukemia (CML) | Blast Phase Chronic Myelogenous Leukemia (CML) | Chronic Phase Phase Chronic Myelogenous Leukemia (CML) | Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)

United States
Mayo Clinic

Withdrawn

Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

B-cell Adult Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | Untreated Adult Acute Lymphoblastic Leukemia | Blastic Phase Chronic Myelogenous Leukemia

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Stage IB Non-Small Cell Lung Carcinoma AJCC v7 | Stage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | ALK Gene Rearrangement | ALK Gene Translocation | ALK...

United States, Guam, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | t(9;22) | BCR-ABL1 Fusion Protein Expression

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

Acute Myeloid Leukemia | High Risk Myelodysplastic Syndrome | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Myeloproliferative Neoplasm | Myeloid Sarcoma | Blasts 10 Percent or More of Bone Marrow Nucleated Cells

United States
Incyte Biosciences UK

Completed

CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | Blastic Phase Chronic Myelogenous Leukemia

United Kingdom, Ireland
Novartis Pharmaceuticals

Completed

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Hypereosinophilic Syndrome | Chronic Myelogenous Leukemia | Systemic Mastocytosis | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

United States, Poland, Italy, Belgium, Canada, France, Australia, Netherlands, Sweden, Switzerland, United Kingdom, Spain, Korea, Republic of, Austria, Germany, Denmark, Finland, Singapore, Taiwan, Hong Kong, New Zealand, Norway
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | B-cell Adult Acute Lymphoblastic Leukemia | Acute Leukemias of Ambiguous Lineage | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Takeda; Amgen

Recruiting

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | t(9;22) | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | BCR-ABL1...

United States
M.D. Anderson Cancer Center

Active, not recruiting

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Myeloid Leukemia With BCR-ABL1

United States
M.D. Anderson Cancer Center

Active, not recruiting

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Acute Lymphoblastic Leukemia | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

Acute Lymphoblastic Leukemia | Down Syndrome | Philadelphia Chromosome Positive | Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Childhood B Acute Lymphoblastic Leukemia | Adult B Lymphoblastic Lymphoma | Ann Arbor Stage I B Lymphoblastic Lymphoma | Ann Arbor Stage... and other conditions

United States, Canada, Puerto Rico, Australia, New Zealand, Switzerland, Ireland
National Cancer Institute (NCI)

Completed

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

B-cell Adult Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blasts More Than 5 Percent of Bone Marrow Nucleated Cells | B Acute Lymphoblastic Leukemia With t(9;22)(q34... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia and other conditions

United States
M.D. Anderson Cancer Center

Active, not recruiting

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Untreated Adult Acute Lymphoblastic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia,... and other conditions

United States
National Cancer Institute (NCI)

Completed

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

Juvenile Myelomonocytic Leukemia | Recurrent Disease | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Childhood Solid Neoplasm | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia... and other conditions

United States, Canada
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Myelofibrosis | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Myeloid Metaplasia | Philadelphia Chromosome-negative CML | Advanced Polycythemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Recurrent Burkitt Lymphoma | Refractory Burkitt Lymphoma | High Grade B-Cell... and other conditions

United States
University of Southern California
National Cancer Institute (NCI); Vasgene Therapeutics, Inc; Whittier Foundation

Terminated

EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Philadelphia Chromosome Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia and other conditions

United States
National Cancer Institute (NCI)

Completed

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Philadelphia Chromosome Negative Chronic Myelogenous... and other conditions

United States
National Cancer Institute (NCI)

Completed

Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult... and other conditions

United States
National Cancer Institute (NCI)

Completed

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

Primary Myelofibrosis | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Disease | Recurrent Adult Acute Lymphoblastic Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic... and other conditions

United States, Canada, New Zealand
National Cancer Institute (NCI)

Active, not recruiting

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

Hematopoietic and Lymphoid Cell Neoplasm | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Adult Acute Lymphoblastic Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic... and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant (GVHD)

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal... and other conditions

United States

Clinical Trials on Knowledge Translation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations